NEW YORK, July 22, 2026, 4:09 p.m. EDT
- RANI finished the session at $0.89, rising 29.4%, with roughly 6.2 million shares changing hands. The main market had closed, but Nasdaq’s after-hours trading was still in progress.
- The surge reduced the stock’s distance from Nasdaq’s $1 minimum to nearly 11%.
- Chief Executive Talat Imran reported acquiring $25,193 worth of shares on the open market in a filing on Tuesday.
Shares of Rani Therapeutics Holdings, Inc. NASDAQ:RANI surged 29.4% on Wednesday, ending the day at $0.89. Despite the gain, the stock finished roughly 11% under Nasdaq’s minimum threshold.
The difference stood at roughly 31% following Tuesday’s $0.69 finish. Rani needs its share price to remain above $1 for at least 10 consecutive sessions before November 9.
This changes the standard to a short-term investor test. Achieving a single close above $1 does not bring the company back into compliance.
The surge occurred in the absence of any fresh clinical data. The most recent operational update from Rani was the RT-114 results, announced on July 15.
The stock rose by 4.3% following the announcement, ending the session at $0.68 with a volume of 868,730 shares changing hands.
Trading volume on Wednesday totaled around 6.2 million, which is 7.9 times higher than the average over the previous five sessions. A more significant move occurred a week after.
| Security | Wednesday move |
|---|---|
| Rani Therapeutics Holdings, Inc. NASDAQ:RANI | Up 29.4% |
| Structure Therapeutics Inc. NASDAQ:GPCR | Added 2.0% |
| Entera Bio Ltd. (NASDAQ:ENTX) | Rose 4.6% |
| SPDR S&P Biotech ETF (NYSEARCA:XBI) | Dropped 1.5% |
Preliminary closing data; not the official exchange figures.
Structure is working on an oral GLP-1 treatment for obesity. Entera is advancing oral peptide medicines, which include an obesity drug candidate.
Neither equaled Rani’s advance. The gap with XBI was roughly 31 percentage points, indicating the move was unique to the company rather than driven by a broader sector trend.
A new filing, Imran’s Form 4 submitted on Tuesday, revealed an open-market buy of 35,000 shares at a price of $0.7198.
The acquisition was priced at $25,193, accounting for approximately 0.6% of Wednesday’s trading volume.
Clinical data are still in the early stages. The open-label Phase 1a trial included 30 healthy participants. Investigators administered a single 12-milligram dose.
Rani Therapeutics reported that oral RT-114 achieved over 150% of the exposure seen with matched subcutaneous administration. The company stated that no serious adverse events were observed.
Imran stated the results “exceeded our expectations.” Rani introduced a 15-participant cohort ahead of an eight-week repeat-dose trial in individuals with obesity. Rani Therapeutics, LLC
The following study is set to begin in 2026, with results expected in 2027.
As of March 31, Rani reported $43.4 million in cash, equivalents and securities. The company subsequently launched an offering expected to raise $20 million in gross proceeds, with shares sold at $1.07 each.
The closing price on Wednesday stayed roughly 17% under the offering price, leaving recent financing investors with holdings still below their acquisition cost.
The investor page for Rani lists no upcoming events for next week. The $1 level remains the most visible short-term indicator.
Risks: The single-administration trial was conducted among healthy subjects and did not demonstrate any effectiveness in patient weight loss. Rani continues to anticipate ongoing losses and states it requires significant extra financing. Delisting from Nasdaq is still a possibility.
